PMID- 16187940
OWN - NLM
STAT- MEDLINE
DCOM- 20060928
LR  - 20220318
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 5 Suppl 1
DP  - 2005 Sep
TI  - Natural killer cell-dendritic cell crosstalk in the initiation of immune 
      responses.
PG  - S49-59
AB  - Dendritic cells (DCs) and natural killer (NK) cells play a critical role in early 
      defences against cancer and infections. They specialise in complementary 
      functions, including IL-12 or IFN-alpha/beta secretion and antigen presentation 
      for the former, and IFN-gamma secretion and killing of infected or tumour cells 
      for the latter. Both DCs and NK cells are also sensors of the immune system that 
      have developed different, but partially overlapping, systems to identify 
      pathology associated danger signals. Evidence of NK-DC interaction has 
      accumulated recently. This interaction may lead to NK cell activation, DC 
      activation, or apoptosis depending on the activation status of both cell types. 
      Thus, the outcome of NK-DC crosstalk is likely to influence both innate and 
      adaptive immune responses. This review addresses the molecular mechanisms 
      under-lying the different NK-DC interactions, and their in vivo significance in 
      anti-tumour or antimicrobial immunity. Finally, we discuss the potential clinical 
      implications of this new field.
FAU - Walzer, Thierry
AU  - Walzer T
AD  - 1INSERM-CNRS-Univ, Centre d'Immunologie de Marseille-Luminy, Mediterranee, Campus 
      de Luminy, case 90, 13288 Marseille cedex 09, France.
FAU - Dalod, Marc
AU  - Dalod M
FAU - Vivier, Eric
AU  - Vivier E
FAU - Zitvogel, Laurence
AU  - Zitvogel L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Cytokines)
RN  - 0 (Membrane Proteins)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (TYROBP protein, human)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Benzamides
MH  - Cell Communication/*immunology
MH  - Clinical Trials as Topic
MH  - Cytokines/metabolism
MH  - Dendritic Cells/drug effects/enzymology/*immunology
MH  - Drug Evaluation, Preclinical
MH  - Gastrointestinal Stromal Tumors/drug therapy/enzymology/immunology
MH  - Herpesviridae Infections/immunology
MH  - Humans
MH  - Imatinib Mesylate
MH  - Killer Cells, Natural/drug effects/enzymology/*immunology
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug 
      therapy/enzymology/immunology
MH  - Membrane Proteins
MH  - Piperazines/pharmacology/therapeutic use
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Proto-Oncogene Proteins c-kit/drug effects/metabolism
MH  - Pyrimidines/pharmacology/therapeutic use
MH  - Receptors, Immunologic/metabolism
MH  - Signal Transduction/immunology
RF  - 78
EDAT- 2005/09/29 09:00
MHDA- 2006/09/29 09:00
CRDT- 2005/09/29 09:00
PHST- 2005/09/29 09:00 [pubmed]
PHST- 2006/09/29 09:00 [medline]
PHST- 2005/09/29 09:00 [entrez]
AID - 10.1517/14712598.5.1.s49 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2005 Sep;5 Suppl 1:S49-59. doi: 10.1517/14712598.5.1.s49.